Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ATNXNASDAQ:CLRBNASDAQ:CLVRNASDAQ:COCP On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATNXAthenex$0.95$0.20▼$23.80$1.76M1.36194,316 shs1.88 million shsCLRBCellectar Biosciences$0.25-1.2%$0.29$0.22▼$3.42$11.48M0.481.15 million shs344,587 shsCLVRClever Leaves$0.00$0.00$0.00▼$3.55$1K3571.181,913 shs1 shsCOCPCocrystal Pharma$1.46$1.44$1.12▼$3.26$14.85M2.1327,983 shs13,448 shsInvesting Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATNXAthenex0.00%0.00%0.00%0.00%0.00%CLRBCellectar Biosciences0.00%+1.67%-20.39%-20.67%-92.22%CLVRClever Leaves0.00%0.00%+100.00%-66.67%-99.99%COCPCocrystal Pharma0.00%+2.82%0.00%-25.13%-29.13%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationATNXAthenex0.1225 of 5 stars0.00.00.04.10.00.00.0CLRBCellectar Biosciences1.7404 of 5 stars3.25.00.00.00.60.00.6CLVRClever LeavesN/AN/AN/AN/AN/AN/AN/AN/ACOCPCocrystal Pharma3.2087 of 5 stars3.55.00.00.03.31.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATNXAthenex 0.00N/AN/AN/ACLRBCellectar Biosciences 2.33Hold$12.504,918.07% UpsideCLVRClever Leaves 0.00N/AN/AN/ACOCPCocrystal Pharma 3.00Buy$7.00379.45% UpsideCurrent Analyst Ratings BreakdownLatest ATNX, CLRB, CLVR, and COCP Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/14/2025CLRBCellectar BiosciencesMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold(Data available from 5/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATNXAthenex$102.82M0.00N/AN/A($3.07) per share0.00CLRBCellectar BiosciencesN/AN/AN/AN/A($0.96) per shareN/ACLVRClever Leaves$17.42M0.00N/AN/A$14.02 per share0.00COCPCocrystal PharmaN/AN/AN/AN/A$2.59 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATNXAthenex-$103.43M-$15.88N/AN/AN/A-86.31%-727.79%-44.44%N/ACLRBCellectar Biosciences-$42.77M-$0.73N/AN/AN/AN/AN/A-191.22%8/11/2025 (Estimated)CLVRClever Leaves-$17.90M-$11.31N/A∞N/AN/AN/AN/A5/26/2025 (Estimated)COCPCocrystal Pharma-$17.98M-$1.57N/AN/AN/AN/A-94.62%-78.24%8/13/2025 (Estimated)Latest ATNX, CLRB, CLVR, and COCP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025COCPCocrystal Pharma-$0.52-$0.23+$0.29-$0.23N/AN/A5/13/2025Q1 2025CLRBCellectar Biosciences-$0.17-$0.13+$0.04-$0.14N/AN/A3/27/2025Q4 2024COCPCocrystal Pharma-$0.55-$0.32+$0.23-$0.32N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthATNXAthenexN/AN/AN/AN/AN/ACLRBCellectar BiosciencesN/AN/AN/AN/AN/ACLVRClever LeavesN/AN/AN/AN/AN/ACOCPCocrystal PharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioATNXAthenex3.081.090.72CLRBCellectar BiosciencesN/A1.771.77CLVRClever LeavesN/AN/AN/ACOCPCocrystal PharmaN/A7.327.32Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipATNXAthenex30.48%CLRBCellectar Biosciences16.41%CLVRClever Leaves6.92%COCPCocrystal Pharma6.72%Insider OwnershipCompanyInsider OwnershipATNXAthenex9.20%CLRBCellectar Biosciences3.70%CLVRClever Leaves8.20%COCPCocrystal Pharma28.14%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableATNXAthenex6528.66 million7.87 millionOptionableCLRBCellectar Biosciences1046.08 million44.38 millionOptionableCLVRClever Leaves5601.76 million1.61 millionNo DataCOCPCocrystal Pharma1010.17 million7.57 millionNot OptionableATNX, CLRB, CLVR, and COCP HeadlinesRecent News About These CompaniesNoble Financial Issues Optimistic Forecast for COCP EarningsMay 23 at 1:53 AM | americanbankingnews.comCocrystal Pharma Reports First Quarter 2025 Financial Results and Provides Updates on its Antiviral Drug-Development ProgramsMay 15, 2025 | globenewswire.comCocrystal Pharma, Inc.: Cocrystal Pharma's Norovirus Oral Antiviral Candidate Demonstrates Potent Activity Against the Emerging GII.17 VariantsApril 24, 2025 | finanznachrichten.deCocrystal Pharma's Norovirus Oral Antiviral Candidate Demonstrates Potent Activity Against the Emerging GII.17 VariantsApril 24, 2025 | globenewswire.comCocrystal Pharma Presents to Investment CommunityApril 23, 2025 | tipranks.comCocrystal Pharma to Present at Life Science Innovation Northwest 2025 ConferenceApril 16, 2025 | globenewswire.comOTC Markets Hosts Virtual Investor Presentation with Dr. Sam Lee, Co-CEO & President, and Jim Martin, Co-CEO & CFO, of Cocrystal Pharma, with David Bautz, PhD, Senior Analyst ...April 10, 2025 | msn.comCocrystal Pharma Approves 2025 Equity Incentive PlanApril 8, 2025 | tipranks.comCOCP: Norovirus Challenge Study Planned for 2025…April 2, 2025 | finance.yahoo.comCocrystal Pharma Reports 2024 Financial Results and Provides Updates on its Antiviral Drug-Development ProgramsMarch 31, 2025 | globenewswire.comCocrystal Pharma to Participate in a Fireside Chat at the Zacks SCR Life Sciences Virtual Investor Forum on March 13, 2025March 6, 2025 | globenewswire.comCocrystal Pharma And 2 Other Promising US Penny Stocks To WatchFebruary 12, 2025 | finance.yahoo.comCocrystal Pharma, Inc. (COCP)January 14, 2025 | finance.yahoo.comCOCP: Phase 2a Trial of CC-42344 Extended…January 9, 2025 | finance.yahoo.comDow Dips Over 100 Points; Cocrystal Pharma Shares SlideDecember 31, 2024 | benzinga.comCocrystal Pharma Shares Fall After Flu-Treatment Study Is ExtendedDecember 31, 2024 | marketwatch.comCocrystal stock plunges 40% on influenza drug updateDecember 31, 2024 | seekingalpha.comCocrystal Pharma to Extend Phase 2a Influenza Challenge Study with Oral PB2 inhibitor CC-42344December 31, 2024 | globenewswire.comCOCP stock touches 52-week high at $3.1 amid market optimismDecember 29, 2024 | investing.comCOCP: Multiple Upcoming Catalysts…November 19, 2024 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeATNX, CLRB, CLVR, and COCP Company DescriptionsAthenex NASDAQ:ATNXAthenex, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapies for the treatment of cancer. It operates through the Oncology Innovation Platform and Commercial Platform segments. The Oncology Innovation Platform segment focuses on the research and development of proprietary drugs. The Commercial Platform segment covers the sale and market of specialty drugs and market development of proprietary drugs. The company was founded by Lyn M. Dyster and David G. Hangauer in November 2003 and is headquartered in Buffalo, NY.Cellectar Biosciences NASDAQ:CLRB$0.25 0.00 (-1.15%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$0.25 +0.00 (+0.76%) As of 05/23/2025 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative with Orano Med to develop CLR 12120 Series; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey.Clever Leaves NASDAQ:CLVR$0.0004 0.00 (0.00%) As of 05/23/2025Clever Leaves Holdings Inc. operates in the botanical cannabinoid and nutraceutical industries. The company operates through two segments, Cannabinoid and Non-Cannabinoid. The Cannabinoid segment cultivates, extracts, manufactures, commercializes, and distributes cannabinoid products comprising cannabis flowers, cannabidiol isolates, full spectrum and standardized extracts, and dry smokable flowers internationally. The Non-Cannabinoid segment formulates, manufactures, markets, sells, distributes, and commercializes nutraceutical and other natural remedies, wellness products, detoxification products, and nutritional and dietary supplements for mass retailers, specialty and health retailers, and distributors in the United States. It also produces extracted products, including isolates, crude oil extracts, and oral solutions; and tetrahydrocannabinol flowers. The company serves retail distributors, pharmaceutical and cannabis companies, and pharmacies. Clever Leaves Holdings Inc. was founded in 2017 and is based in Tocancipá, Colombia.Cocrystal Pharma NASDAQ:COCP$1.46 0.00 (0.00%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$1.43 -0.03 (-2.05%) As of 05/23/2025 07:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, norovirus, and respiratory virus infections. The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that has completed Phase II a clinical trial to treat HCV infection; and CC-42344, a PB2 inhibitor that has completed Phase I clinical trial for treating influenza infection. It is also involved in identifying and developing non-nucleoside polymerase inhibitors for norovirus infections. Cocrystal Pharma, Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; and a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections. The company is headquartered in Bothell, Washington. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/19 - 05/23 Trade Desk Silences Critics; Recovery Looks Poised to Continue Alphabet Stock Lags—But Waymo May Be Its Hidden Driver This Market Sell-Off Might Trigger a Value Rotation Into Pepsi Booz Allen Hamilton Earnings: 3 Bullish Signals for BAH Stock Turbulence for Joby Shares: What's Behind the Recent Dip? Pfizer's 7.5% Dividend: Income Haven or House of Cards? TJX Stock Price Stumble Is Your Chance to Pick Up a Bargain Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
